经导管肝动脉化疗栓塞联合索拉非尼治疗中晚期肝细胞癌的临床观察

Clinical observation of transarterial chemoembolizafion combined with sorafenib for advanced hepatocellular carcinoma

目的 观察经导管肝动脉化疗栓塞（TACE）联合索拉非尼治疗中晚期肝细胞癌的有效性和安全性.方法 40例已接受过TACE治疗的中晚期肝细胞癌患者口服索拉非尼单药治疗,400mg,2次/d,直至病情进展或出现不可耐受的毒性反应.按照实体瘤疗效评价标准（RECIST）评价疗效,按照美国国立癌症研究所常见毒性事件标准（NCI-CTCAE）评价不良反应.结果 40例中晚期肝细胞癌患者中,获得完全缓解1例,部分缓解7例,疾病稳定19例,疾病进展13例,疾病控制率为67.5%.全组患者的生存时间为1～18个月,1年生存率为54.0%.主要不良反应为手足皮肤反应,其次是腹泻和血小板计数降低.结论 TACE联合索拉非尼治疗中晚期肝细胞癌是有效和安全的.

Objective To observe the efficacy and side effects of transarterial chemoembolization （TACE） combined with sorafenib for advanced hepatocellular carcinoma （HCC）. Methods Forty patients with HCC were treated with sorafenib （400 mg bid） after TACE. The efficacy was evaluated according to RECIST 1. 1 criteria, and side effects were assessed by NCI CTC 3.0 criteria. Results Among the forty cases, one case achieved complete remission （CR）, seven cases achieved partial remission （PR） , nineteen cases achieved stable disease （SD） and thirteen cases had progressive disease （PD）. The disease control rate （DCR） was 67.5%. The overall survival time was 1-18 months, and 1 -year survival rate was 54.0%.The major adverse events were hand-foot skin reaction, diarrhea and thrombocytopenia. Conclusion The combined therapy of TACE and sorafenib is effective and well tolerated for advanced HCC.